Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.